Stocks Decline Pre-Bell Ahead of Latest PPI Report; Asia, Europe Rise
US equity markets were tracking in the red before the opening bell Thursday as investors await last
US equity markets were tracking in the red before the opening bell Thursday as investors await last
There are also a bunch of companies that may be removed from the Nasdaq-100 as part of its reconstitution before the end of the year.
U.S. equities were slightly higher around midday ahead of a key report on consumer prices due tomorrow.
In so doing, Polymarket's founder demonstrated a real-world consumer use case for crypto, earning him a spot on CoinDesk's Most Influential 2024 list.
On Monday, the FDA approved Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen. Acetaminophen, a common over-the-counter pain reliever and fever reducer, is the leading cause of acute liver failure in the United States. Eac
CAF will deliver 13 metro trains to Metro de Medellín and six metro units to Metro Santiago.
Google said that a math equation that would take a classical supercomputer longer than the whole history of the universe to solve takes only five minutes using a quantum computer powered by its new Willow chip.
A regulatory filing showed C3.ai founder and CEO Thomas Siebel was selling 12.78 million shares of the artificial intelligence software company
On Monday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. The study’s primary endpoint of progression-free survival (PFS) was met at primary analysis, demonstrating pirtobrutinib was superior to the investigator’s choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR). A
HealthEquity shares fell Tuesday after the company's full-year profit and sales outlook missed analysts' estimates.